Talaris Therapeutics, Inc. announced the appointment of Mary Kay Fenton as President effective as of May 26, 2023. Ms. Fenton, who will continue as the company's Chief Financial Officer, succeeds Chief Executive Officer Scott Requadt who will be leaving the company as part of a planned workforce reduction, as previously announced by the company. Talaris is currently conducting a comprehensive review of strategic alternatives focused on maximizing shareholder value, including possible business combinations and/or a divestiture of the company's cell therapy CMC capabilities.

The company has not set a timetable for completion of this strategic review and does not intend to comment further on the status of this process unless or until its Board of Directors has approved a definitive course of action, or it is determined that other disclosure is appropriate.